Oslo, Norway (12 June 2020) - NattoPharma continues to see a strong demand for our products during the second quarter, and we are experiencing Q2 revenue to be in the range of NOK 44-54 million resulting in a H1-2020 revenue in the range of NOK 100-110 million. This is more than 70% growth compared to H1-2019. The Adj. EBITDA margin is expected to be in excess of 15% for H1-2020, compared to the current guiding of 10-15% for the full year.
The current performance builds on our confidence to deliver on the guiding for the full year as communicated during the Q1 release. During the second quarter we have continued to see a strong demand for dietary supplements and in particular our clinically validated products.
NattoPharma will provide more detailed insight and guidance during the H1 release scheduled at July 15th, 2020.
For more information, please contact:
Robert Schrama, CFO
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities